always better to have 'material events' than Tweet
Post# of 30028
Posted On: 11/06/2014 8:41:11 PM
always better to have 'material events' than Tweets or blogs
***** 7 weeks remaining w/ 12 milestone deliverables *****
2b.) LymPro - incl. patients w/ mild AZ, enrollment 68 patient LP-002 exten. (est. 4Q14)
03.) LymPro - JV Partnership Agreement (end of summer / rev. to est. 4Q14)
05.) LymPro - Partner valid. of APP & CLIA cert. (est. 4Q14)
06.) Eltoprazine - 200 patient Ph. 2b trial PD-LID (est. 4Q14)
07.) Eltoprazine - US IND filed & apvd. for PD-LID (est. 4Q14)
08.) MANF - Ophthalmological ear toxicology complete data sets (est. 4Q14)
10.) MANF / GDNF - Renishaw CED Ph. 2B test trial results (est. 4Q14)
12.) MANF OIS - Ocular Ischemic Syndrome - ODD applic. filed (est. 4Q14)
13.) MANF DB-1 Wolframs - Retinal eye data test results (est. 4Q14)
14.) MANF DB-1 Wolframs - orphan potential (est. 4Q14)
15.) MANF - Good Mfg. Practices (GMP) for 1st in-man studies (est. 4Q14)
25.) NASDAQ up-listing - (est. 4Q14)
***** 7 weeks remaining w/ 12 milestone deliverables *****
2b.) LymPro - incl. patients w/ mild AZ, enrollment 68 patient LP-002 exten. (est. 4Q14)
03.) LymPro - JV Partnership Agreement (end of summer / rev. to est. 4Q14)
05.) LymPro - Partner valid. of APP & CLIA cert. (est. 4Q14)
06.) Eltoprazine - 200 patient Ph. 2b trial PD-LID (est. 4Q14)
07.) Eltoprazine - US IND filed & apvd. for PD-LID (est. 4Q14)
08.) MANF - Ophthalmological ear toxicology complete data sets (est. 4Q14)
10.) MANF / GDNF - Renishaw CED Ph. 2B test trial results (est. 4Q14)
12.) MANF OIS - Ocular Ischemic Syndrome - ODD applic. filed (est. 4Q14)
13.) MANF DB-1 Wolframs - Retinal eye data test results (est. 4Q14)
14.) MANF DB-1 Wolframs - orphan potential (est. 4Q14)
15.) MANF - Good Mfg. Practices (GMP) for 1st in-man studies (est. 4Q14)
25.) NASDAQ up-listing - (est. 4Q14)
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼